CN1075141A - 1,4-二氢吡啶-3,5-二甲酸酯的制备及用途 - Google Patents
1,4-二氢吡啶-3,5-二甲酸酯的制备及用途 Download PDFInfo
- Publication number
- CN1075141A CN1075141A CN93101011A CN93101011A CN1075141A CN 1075141 A CN1075141 A CN 1075141A CN 93101011 A CN93101011 A CN 93101011A CN 93101011 A CN93101011 A CN 93101011A CN 1075141 A CN1075141 A CN 1075141A
- Authority
- CN
- China
- Prior art keywords
- propyl
- formula
- compound
- reaction
- dihydropyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 230000000302 ischemic effect Effects 0.000 claims abstract description 10
- 230000004089 microcirculation Effects 0.000 claims abstract description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 18
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 18
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 10
- 150000003935 benzaldehydes Chemical class 0.000 claims description 9
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003513 alkali Substances 0.000 claims description 7
- -1 3-n-propyl Chemical group 0.000 claims description 6
- 239000012442 inert solvent Substances 0.000 claims description 6
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 claims description 4
- 230000002152 alkylating effect Effects 0.000 claims description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 3
- 229910052786 argon Inorganic materials 0.000 claims description 2
- 150000003053 piperidines Chemical class 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- MCVVUJPXSBQTRZ-ONEGZZNKSA-N methyl (e)-but-2-enoate Chemical compound COC(=O)\C=C\C MCVVUJPXSBQTRZ-ONEGZZNKSA-N 0.000 claims 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 210000004204 blood vessel Anatomy 0.000 abstract description 4
- 230000002490 cerebral effect Effects 0.000 abstract description 2
- 230000002093 peripheral effect Effects 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 238000000034 method Methods 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 4
- 206010003497 Asphyxia Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000001720 action spectrum Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229910001038 basic metal oxide Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- JYCKNDWZDXGNBW-UHFFFAOYSA-N dipropyl sulfate Chemical compound CCCOS(=O)(=O)OCCC JYCKNDWZDXGNBW-UHFFFAOYSA-N 0.000 description 1
- JTTLZQCZNHQIFK-UHFFFAOYSA-L disodium ethyl acetate sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCOC(C)=O JTTLZQCZNHQIFK-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000008698 shear stress Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
本发明涉及新的2,6-二甲基-1-正丙基-4-
(4-三氟甲基苯基)-1,4-二氢吡啶-3,5-二甲酸二
甲酯、其制备方法及其药物用途,用于由微循环紊乱
引起的局部缺血症。该作用可以发生在外围和大脑
血管系统中。
Description
本发明涉及新的2,6-二甲基-1-正丙基-4-(4-三氟甲基苯基)-1,4-二氢吡啶-3,5-二甲酸二甲酯、其制备方法及其药物用途,用于由微循环紊乱引起的局部缺血症。该作用可以发生在外围和大脑血管系统中。
人们知道,1,4-二氢吡啶二甲酸具有钙拮抗或钙紧张作用,从而可用作血管影响剂和循环影响剂。参见:
[cf.German Offenlegungsschrift 2,506,987;German Offenlegungsschrift 2,210,667]。
EP240828也描述了具有血液流变性质的具有降血压的1,4-二氢吡啶。
本发明涉及新的式(Ⅰ)的2,6-二甲基-1-正丙基-4-(4-三氟甲基苯基)-1,4-二氢吡啶-3,5-二甲酸二甲酯
它具有惊人的血液流变作用能力和改善循环(特别是微循环)的能力,同时对血压不产生影响。因而,它特别适用于急性和慢性局部缺血症的控制。
本发明的式(Ⅰ)化合物可按常规方法制备,例如,采用下述方法
[A]在惰性溶剂中,必要时在碱/酸存在下,将式(Ⅱ)的2-(4-三氟甲基亚苄基)乙酰乙酸甲酯直接与3-正丙基氨基巴豆酸甲酯反应,或者与乙酰乙酸甲酯和正丙基胺盐酸盐反应,式(Ⅱ)如下:
或者,
[B]在吡啶中,将式(Ⅲ)的4-三氟甲基苯甲醛与乙酰乙酸甲酯和正丙基胺盐酸盐反应,或者与正丙基胺和吡啶盐酸盐反应。式(Ⅲ)如下:
或者
[C]首先,在保护性气氛中,用3-正丙基氨基巴豆酸甲酯在惰性溶剂中处理Lewis酸(最好是四氯化钛),同时使用碱(最好是哌啶),然后加入式(Ⅲ)的4-三氟甲基苯甲醛,或者
[D]在惰性溶剂中,在碱存下将式(Ⅳ)的2,6-二甲基-4-(4-三氟甲基苯基)-1,4-二氢吡啶-3,5-二甲酸二甲酯与烷基化试剂(最好是正丙基碘或三氟甲磺酸正丙酯)反应。式(Ⅳ)如下:
本发明方法可用下列反应式举例说明:
可能的溶剂是水或在反应条件下不产生变化的有机溶剂。这些溶剂。这些溶剂最好包括醇类,例如甲醇、乙醇、丙醇、异丙醇、丁醇;醚类,例如乙醚、二氧六环、四氢呋喃、乙二醇单甲醚或乙二醇二乙醚;或酰胺类,例如二甲基甲酰胺,二甲基乙酰胺或六甲基磷酰胺;或冰乙酸、二甲基亚砜、乙腈或吡啶。优选1,2-二甲氧基乙烷、吡啶和丁醇。
根据具体的反应过程,可用的碱是氢化物,例如氢氢化钠;碱金属或碱土金属氢氧化物,例如氢氧化钠或氢氧化钾;烷氧化物,例如叔丁醇钾;或吡啶。优选的是氢化钠和吡啶。
所用的酸通常是盐酸和硫酸。
反应温度可以在较宽的温度回变化,反应一般在+10℃到150℃间进行,最好在+20℃到+100℃间,尤其在相应溶剂的沸点下进行。
反应可以在常压,也可以在加压或减压下进行。通常在常压下进行。
当实施本发明的A、B、C、D各过程时,参加反应物质的比值可任意确定。但是,反应一般以反应物的摩尔量进行。本发明的物质最好用下述方法分离和纯化:即,真空蒸去溶剂,并将残余物重结晶,只经冰冷却后便可从适当的溶剂中得到结晶的本发明物质。有时必须用色谱法纯化本发明化合物。
式(Ⅱ)化合物是公知的,可按常规方法制备[Cf.H.Dornow and W.Sassenberg,Liebigs Ann.Chem.602,14(1957)]。
4-三氟甲基苯甲醛(Ⅲ)也是公知的[Cf.Beilstein 7(3),1013]。
反应中可用的烷基化试剂是:例如,正丙基囟化物,最好是正丙基碘、三氟甲磺酸正丙酯或硫酸二正丙酯。
烷基化是在常压下,于0℃至+150℃(最好在室温至+100℃),在上述溶剂中进行的。
该新化合物显示出不可预见的实用的药理作用谱。
在不超过10mg/Kg静注和30mg/Kg口服的剂量范围内对血管和血压的影响很小,同时它能够通过影响红细胞的变形性并抑制白红胞的粘着性和活性来增加循环,尤其是微循环。
对血压的影响很小可用下述模型测定,该模型对于二氢吡啶特别适用,即,SH大鼠口服给药后测定尾动脉(Riva Rocci法);和麻醉的Wistar大鼠静脉给药后用导管测量颈动脉。由于该化合物在上述两种试验模型中在给定剂量下不降低血压,所以被称为缺乏对血压的影响。
治疗剂量和血压作用之间的差异因子至少为100。
因此,本发明化合物可用于制药,以治疗急性和慢性局部缺血症,例如间歇性跛行、心肌梗塞、大脑梗塞以及再灌注损伤和和休克。
下面的体内和体外试验表明了特别选择的本发明化合物的使人感兴趣的作用。
(Ⅰ)红细胞功能
红细胞的变形性在急性或慢性局部缺血症的发病起源和过程中起着重要的作用,它们决定了血液粘度,从而决定了在其微循环中的分布。
用下面的试验检测各测定物:
试验a)检测物质的抗溶血作用(ED50,mol/l)。在该试验中,将钙充满的红细胞在高剪切应力下压过小孔,使血红蛋白释放出来,并测定之,作为它们溶血的表达。测定量是血红蛋白释放的减少。
试验b)是在玻璃毛细管(25μm直径)中,在狭窄区后面的管内,产生低剪切应力下,检测红细胞混悬液的粘度。细胞外的钙增加该粘度。
a)在红细胞中的抗溶血作用
在高剪切应力下,正常的红细胞变成溶血性的。钙充满细胞的溶血特别明显。力学稳定性测量用来表征物质的性质。测定的量是在介质中游离血红蛋白的浓度。
b)在玻璃毛细管中的粘度
与循环有关的生物物理相互作用可以用玻璃毛细管(直径20-30μm)测定。最终粘度取决于细胞的状态。充满钙时,粘度增加。相对于受损份的但未处理的对照组在0.7Pa下的粘度增加百分数如下。试验剂量是10-8g/ml。
表Ⅰ
实施例号 效应(%)
本发明化合物(Ⅰ) 190
Ⅱ)白细胞作用
微循环可以在食鼠颊窝模型中直接观察到。测定的量是白细胞的粘连以及容器直径和红细胞沉降速率。粘连在局部缺血和非局部缺血试验条件下测定。在非局部缺血条件下,将粘连在小静脉中定量而在局部缺血条件下(循环停止10分钟),则在小动脉中定量。对照实验的结果调节至100%。每一种情况下选用的试验剂量是0.1mg/Kg静注,结果表示为与对照组比较降低的百分数。令人惊奇的是,在局部缺血条件下,0.03mg/Kg静注剂量的物质似乎仍起作用。这对于适应症的治疗特别有利。
表Ⅱ
实施例号 非局部缺血 局部缺血
对照组=100% 对照组=100%
本发明化合物(Ⅰ) 55% 37%
Ⅲ)血压
临床知识表明:二氢吡啶的抗局部缺血作用常常被血管舒张作用所掩蔽,因此,人们致力了寻找血压非活的(即:血流变性作用和降血压作用之差≥10)DHP,下表示出的是口服给药(SH大鼠)或静注给药(麻醉的Wistar大鼠)时出现血压降低的剂量。
表Ⅲ
实施例号 口服(mg/Kg) 静注(mg/Kg)
本发明化合物(Ⅰ) >30 >10
表Ⅲ说明,与模型Ⅱ比较,治疗作用和血压作用(静注)之差至少是100。
可以按已知方法,采用惰性、无毒、药学上可接受的赋形剂或溶剂,将新的活性物质转变为常规制剂,例如:片剂、包衣片剂、丸剂、粒剂、气雾剂、糖浆、乳剂、混悬剂和溶液。这时,治疗活性化合物在每一剂型中的浓度为混合物总重量的约0.5-90%,即用量应足以达到所示的剂量范围。
例如,可以用溶剂和/或赋形剂稀释活性物质,必要时使用乳化剂和/或分散剂来制剂。例如,当使用水作稀释剂时,可以用有机溶剂作辅助溶剂。
以常规方式给药,最好是口服或非肠道给药,尤其是舌下或静脉给药。
通常,已经证明,静脉给予约0.001-1mg/Kg,最好约0.01-0.5mg/Kg体重的剂量有利于达到效果,口服给药时剂量是约0.01-20mg/Kg,最好是10mg/Kg体重。
尽管如此,有时必须偏离上述剂量,这明确地取决于患者体重或用药途径的类型;取决于对药物的个体反映、制剂的方式和给药发生的地点和间隔。因此,有时用比上述剂量少的剂量便足够了,而在另一些情况下必须超过所述上限。当给药量相对较大时,最好将剂量分为一天数次。
制备实施例
实施例1
2,6-二甲基-1-正-丙基-4-(4-三氟甲基苯基)-1,4-二氢吡啶-3,5-二甲酸二甲酯
(方法D)
1)将2.95g(0.008mol)2,6-二甲基-4-(4-三氟甲基苯基)-1,4-二氢吡啶-3,5-二甲酸二甲酯溶解于25ml 1,2-二甲氧基乙烷中,用浓度为80%的氢化钠(0.30g,0.01mol)处理,30分钟后,和1.70g(0.01mol)正丙基碘处理。混合物于室温下搅拌3小时,用稀盐酸稀释,真空蒸发。残余物经硅胶色谱纯化(二氯甲烷)。产量:1.02g(收率:31.0%)m.p.102-104℃。
(方法D)
2)在氩气氛中,用1.84g(0.005mol)2,6-二甲基-4-(4-三氟甲基苯基)-1,4-二氢吡啶-3,5-二甲酸二甲酯在0℃下处理0.3g(0.01mol)浓度为80%的氢化钠的二甲基甲酰胺(30ml,p.a.)溶液。然后缓慢加入1.92g(0.01mol)三氟甲磺酸正丙酯的二氯甲烷(30ml)溶液(由三氟甲磺酸酐和正丙醇在等当量的吡啶存在下在二氯甲烷中制得),混合物于0℃搅拌1h。用水处理后,用二氯甲烷提取。用硫酸镁干燥,蒸发。残余物经硅胶柱色谱纯化,以二氯甲烷洗脱。
产量:1.16g(收率:56.6%)
m.p.100-103℃
(方法B)
3)将5.22g(0.03mol)4-三氟甲基苯甲醛,7.04g(0.06mol)乙酰乙酸甲酯和2.87g(0.03mol)正丙基胺盐酸盐[或1.78g(0.03mol)正丙基胺和3.47g(0.03mol)吡啶盐酸盐]的混合物在20ml吡啶中加热回流20小时。蒸去吡啶后,将混合物分配于水和二氯甲烷中,有机相用水洗,用硫酸镁干燥并蒸发,残留物用甲醇重结晶。
m.p.:102-104℃
产量:3.1g(收率:25.1%)
方法C
4)在氮保护下,先后将四氯化钛(0.55ml,5mmol)和派啶(1ml,10mmol)加到甲苯(20ml)中,搅拌5分钟。滴加3-正丙基氨基巴豆酸甲酯(3.14g,20mmol),再加入4-三氟甲基苯甲醛(1.36ml,10mmol),混合物于室温下搅拌3小时。为便于操作,加入100ml浓度为5%的盐酸,有机相用乙酸乙酯溶解,依次用5%盐酸和碳酸氢钠溶液洗涤。用硫酸钠干燥乙酸乙酯溶液,蒸发,残余物在正庚烷中搅拌,得产物1.59g(收率38.7%)。
m.p.100-102℃
方法A
5)将3.72g(0.039mol)正丙基胺盐酸盐加到由乙酰乙酸甲酯(3.9g,0.03mol)、2-(4-三氟甲基亚苄基)-乙酰乙酸甲酯(8.16g,0.03mol)和吡啶(50ml)组成的溶液中,加热回流5小时。将反应产物真空浓缩,残余物溶于二氯甲烷和水中,分去水相,二氯甲烷溶液用硫酸钠干燥,蒸发。残余物用硅胶色谱纯化,以二氯甲烷为溶剂。将其溶于正庚烷,静置重结晶得1.93产物(收率15.6%)。
m.p.:102-104℃
Claims (6)
2、权利要求1的化合物用于急性和慢性局部缺血症的控制。
3、式(Ⅰ)化合物2,6-二甲基-1-正丙基-4-(4-三氟甲基)-1,4-二氢吡啶-3,5-二甲酸二甲酯的制备方法
其特征在于:
[A]在惰性溶剂中,必要时在碱/酸存在下,将式(Ⅱ)的2-(4-三氟甲基亚苄基)乙酰乙酸甲酯直接与3-正丙基氨基巴豆酸甲酯反应,或者与乙酰乙酸甲酯和正丙基胺盐酸盐反应,式(Ⅱ)如下:
或者,
[B]在吡啶中,将式(Ⅲ)4-三氟甲基苯甲醛与乙酰乙酸甲酯和正丙基胺盐酸盐反应,或者与正丙基胺和吡啶盐酸盐反应,式(Ⅲ)如下:
或者
[C]首先,在保护性气氛中,用3-正丙基氩基巴豆酸甲酯在惰性溶剂中处理Lenis酸(最好是四氯化钛),同时使用碱(最好是哌啶),然后加入式(Ⅲ)的4-三氟甲基苯甲醛,或者
[D]在惰性溶剂中,在碱存在下将式(Ⅳ)的2,6-二甲基-4-(4-三氟甲基苯基)-1,4-二氢吡啶-3,5-甲酸二甲酯与烷基化试剂(最好是正丙基碘或三氟甲磺酸正丙酯)反应,式(Ⅳ)如下:
4、含有权利要求1化合物的药物。
5、药物生产方法,其特征在于将权利要求1化合物转化为适当的给药剂型,必要时可使用常规助剂和赋形剂。
6、用权利要求1化合物来控制由微循环紊乱引起的局部缺血症。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4200714A DE4200714A1 (de) | 1992-01-14 | 1992-01-14 | Spezieller 1,4-dihydropyridin-3,5-dicarbonsaeureester, verfahren zu seiner herstellung und seine pharmazeutische verwendung |
DEP4200714.3 | 1992-01-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1075141A true CN1075141A (zh) | 1993-08-11 |
Family
ID=6449473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN93101011A Pending CN1075141A (zh) | 1992-01-14 | 1993-01-14 | 1,4-二氢吡啶-3,5-二甲酸酯的制备及用途 |
Country Status (14)
Country | Link |
---|---|
US (1) | US5342847A (zh) |
EP (1) | EP0551663A1 (zh) |
JP (1) | JPH0616633A (zh) |
KR (1) | KR930016399A (zh) |
CN (1) | CN1075141A (zh) |
AU (1) | AU3108393A (zh) |
CA (1) | CA2087245A1 (zh) |
CZ (1) | CZ396492A3 (zh) |
DE (1) | DE4200714A1 (zh) |
HU (1) | HUT70155A (zh) |
IL (1) | IL104357A0 (zh) |
MX (1) | MX9300057A (zh) |
PL (1) | PL297393A1 (zh) |
ZA (1) | ZA93210B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102453242A (zh) * | 2010-10-27 | 2012-05-16 | 中国科学院大连化学物理研究所 | 一种直接酯化聚合制备聚呋喃二甲酸酯的方法 |
CN103044316A (zh) * | 2013-01-23 | 2013-04-17 | 石家庄学院 | 一种以咪唑离子液体为催化剂制备1,4-二氢吡啶的方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4223867A1 (de) * | 1992-07-20 | 1994-01-27 | Bayer Ag | Spezieller 1,4-Dihydropyridin-3,5-dicarbonsäureester, Verfahren zu seiner Herstellung und seine pharmazeutische Verwendung |
CH692199A8 (fr) | 1997-10-09 | 2002-06-14 | Cermol S.A. | Composes pyridiques et compositions pharmaceutique |
CN103998038A (zh) * | 2011-11-24 | 2014-08-20 | 里皮达特发展研究及咨询公司 | 具有hsp调节活性的1,4-二氢吡啶衍生物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3883543A (en) * | 1969-05-10 | 1975-05-13 | Bayer Ag | N-alkyl-1,4-dihydropyridines |
DE2210667A1 (de) * | 1972-03-06 | 1973-09-20 | Bayer Ag | Kondensiert aromatisch substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
US3956341A (en) * | 1974-02-21 | 1976-05-11 | Smithkline Corporation | 1,3,5-Tricarbo-1,4-dihydropyridines |
US4975440A (en) * | 1984-09-28 | 1990-12-04 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Optically-active 1,4-dihydropyridine |
EP0176956B1 (de) * | 1984-09-28 | 1994-06-15 | Byk Gulden Lomberg Chemische Fabrik GmbH | Neue Diarylverbindungen |
US4771057A (en) * | 1986-02-03 | 1988-09-13 | University Of Alberta | Reduced pyridyl derivatives with cardiovascular regulating properties |
US4780538A (en) * | 1986-02-12 | 1988-10-25 | Merck & Co., Inc. | Process for 1,4-dihydropyridine compounds using a titanamine catalyst |
DE4011695A1 (de) * | 1990-04-11 | 1991-10-17 | Bayer Ag | Verwendung von n-alkylierten 1,4-dihydropyridindicarbonsaeureestern als arzneimittel, neue verbindungen und verfahren zu ihrer herstellung |
-
1992
- 1992-01-14 DE DE4200714A patent/DE4200714A1/de not_active Withdrawn
- 1992-12-29 CZ CS923964A patent/CZ396492A3/cs unknown
- 1992-12-31 EP EP92122179A patent/EP0551663A1/de not_active Withdrawn
-
1993
- 1993-01-07 AU AU31083/93A patent/AU3108393A/en not_active Abandoned
- 1993-01-08 MX MX9300057A patent/MX9300057A/es unknown
- 1993-01-11 IL IL104357A patent/IL104357A0/xx unknown
- 1993-01-12 PL PL29739393A patent/PL297393A1/xx unknown
- 1993-01-13 CA CA002087245A patent/CA2087245A1/en not_active Abandoned
- 1993-01-13 ZA ZA93210A patent/ZA93210B/xx unknown
- 1993-01-13 KR KR1019930000354A patent/KR930016399A/ko not_active Application Discontinuation
- 1993-01-13 HU HU9300075A patent/HUT70155A/hu unknown
- 1993-01-13 JP JP5019454A patent/JPH0616633A/ja active Pending
- 1993-01-14 CN CN93101011A patent/CN1075141A/zh active Pending
- 1993-01-16 US US08/001,017 patent/US5342847A/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102453242A (zh) * | 2010-10-27 | 2012-05-16 | 中国科学院大连化学物理研究所 | 一种直接酯化聚合制备聚呋喃二甲酸酯的方法 |
CN102453242B (zh) * | 2010-10-27 | 2013-05-22 | 中国科学院大连化学物理研究所 | 一种直接酯化聚合制备聚呋喃二甲酸酯的方法 |
CN103044316A (zh) * | 2013-01-23 | 2013-04-17 | 石家庄学院 | 一种以咪唑离子液体为催化剂制备1,4-二氢吡啶的方法 |
Also Published As
Publication number | Publication date |
---|---|
HU9300075D0 (en) | 1993-04-28 |
HUT70155A (en) | 1995-09-28 |
MX9300057A (es) | 1993-09-01 |
PL297393A1 (en) | 1993-10-04 |
AU3108393A (en) | 1993-07-15 |
EP0551663A1 (de) | 1993-07-21 |
ZA93210B (en) | 1993-09-09 |
JPH0616633A (ja) | 1994-01-25 |
DE4200714A1 (de) | 1993-07-15 |
CZ396492A3 (en) | 1993-12-15 |
KR930016399A (ko) | 1993-08-26 |
IL104357A0 (en) | 1993-05-13 |
US5342847A (en) | 1994-08-30 |
CA2087245A1 (en) | 1993-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100509799C (zh) | 一种合成非手性,非肽类的抗凝血酶抑制剂的方法 | |
US4154839A (en) | 2,6-Dimethyl-3-carboxymethoxy-4-(2-nitrophenyl)-5-carbisobutoxy-1,4-dihydropyridine | |
JP2895145B2 (ja) | 鎮痛剤として用いられるn―フエニル―n―(4―ピペリジニル)アミド | |
CN1272319C (zh) | 制备氨氯地平马来酸盐的工艺、所制得的氨氯地平马来酸盐、其药物组合物和用途 | |
CN1212622A (zh) | 应用PPARα或PPARγ拮抗剂治疗X综合征 | |
WO2005121123A1 (fr) | Composes utilises comme antagonistes de ccr5 | |
WO1999037617A1 (en) | Chemokine receptor antagonists and methods of use therefor | |
IE41528B1 (en) | Benzomorphanes and derivatives and pharmaceutical compositions containing the same | |
JP3012352B2 (ja) | 薬剤としてのn−アルキル化1,4−ジヒドロピリジンジカルボン酸エステル類の使用、新規化合物およびそれらの製造方法 | |
CN1075141A (zh) | 1,4-二氢吡啶-3,5-二甲酸酯的制备及用途 | |
US20050137405A1 (en) | Process for making amlodipine, derivatives thereof, and precursors therefor | |
EP0688771A1 (de) | Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe | |
EP0238281B1 (en) | Selective alpha-adrenergic receptor antagonists | |
WO2009092301A1 (zh) | 二氢吡啶类钙拮抗剂化合物及其制备方法与医药用途 | |
CN1777586A (zh) | 稳定的无定形樟脑磺酸氨氯地平、其制备工艺以及其口服给药的组合物 | |
JPS6213952B2 (zh) | ||
EP2306826A1 (en) | Salts of methyl 2-((r))-(3-chlorophenyl)((r)-1-((s)-2-(methylamino)-3((r)-tetrahydro-2h-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate | |
JPH0633247B2 (ja) | 3―アミノプロポキシフェニル誘導体およびその製法ならび用途 | |
CN1956956A (zh) | 龙胆酸氨氯地平及其制备方法 | |
CN1085548A (zh) | 特殊的1,4-二氢吡啶-3,5-二羧酸酯及其制备方法以及其药用用途 | |
IE42131B1 (en) | New aryloxy n-aralkyl propanolamines,their preparation andpharmaceutical compositions containing them | |
CA1262906A (en) | 3-(2-furoyl)-5-alkoxycarbonyl-2,6-dimethyl-4- (2-nitrophenyl)-1,4-dihydropyridine calcium antagonists | |
US6444821B2 (en) | Crystals of piperidine derivatives, intermediates for production of the same, and process for producing the same | |
US4675329A (en) | Isopropyl 2-(3-trifluoromethylphenoxy)-ethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate as vaso-dilators | |
SE441447B (sv) | 2-hydroxi-5-/1-hydroxi-2-/4-(2-oxo-1-bensimidazolinyl)-piperidino/etyl/bensoesyraderivat och sett att framstella dessa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication |